California Governor Gavin Newsom has signaled that the state would pursue manufacturing insulin to offer the hormone at a reduced cost to people with diabetes. “Insulin should not drain your bank account,” Newsom shared over Twitter. Newsom has also made contract manufactured insulin part of the proposed budget planning for the fiscal year 2022. Get […]
Lilly pays $50 million upfront to use Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology
Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology. Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products intended for the nervous system. Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities. Get the full story […]
European regulators approve Janssen’s twice-yearly schizophrenia treatment
Two months after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), Janssen has won approval from the European Commission for Byannli, a six-month formulation of paliperidone palmitate. Indicated as a maintenance treatment for adults with schizophrenia, Byannli won approval based on results from the Route 6 study, which found […]
Baxter bolsters fill-finish capabilities with $100M investment in Germany
Baxter International (NYSE:BAX) plans to invest roughly $100 million to expand a sterile fill-finish manufacturing plant in Halle/Westfalen, Germany. BioPharma Solutions (BPS), a subsidiary of Deerfield, Illinois–based Baxter, will manage the new facility. BPS supports pharmaceutical companies through a range of offerings, including scientific support, sterile contract manufacturing and parenteral delivery systems. Get the full […]
AbbVie, University of Chicago lengthen oncology research partnership until 2025
AbbVie (NYSE: ABBV) has extended an agreement with the University of Chicago related to collaborative preclinical oncology research. The North Chicago, Illinois–based company and the university are working together on research involving biomarkers and therapeutic applications related to existing AbbVie programs. In the past, the organizations have also explored new drug delivery methods to improve […]
Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings
Merck & Co. (NSDQ:MRNA) scientists have explored fighting cancer by way of the STING (stimulator of interferon genes)-controlled innate immune pathway. Now, the company has published research in Advanced Therapeutics detailing a preclinical study with its partner Vesselon Inc. that reported impressive pharmacokinetics results related to MSA-1, a STING agonist. The researchers found that low […]
Rani Therapeutics’ stock jumps 69% after IPO
Rani Therapeutics Holdings (NSDQ:RANI) recently announced the closing of its initial public offering (IPO) of 7,666,667 shares of its Class A common stock. The stock began trading at $11, trailing the company’s expected range of $14 to $16. Today, the stock closed at $18.61, representing a 69.18% increase. RANI shares were trading even higher on […]
Philip Morris and Carlyle continue bidding war over Vectura
The drama surrounding the inhalable drug delivery specialist Vectura (LON:VEC) continues. On Monday, Philip Morris boosted its offer to acquire Vectura to 165 pence ($2.30) per share, beating Carlyle’s latest offer of 155 pence ($2.16). In July, Philip Morris (NYSE:PM) agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion, drawing criticism from the American […]
Rani Therapeutics prices $73M IPO for robotic drug-delivery pill tech
Rani Therapeutics Holdings (NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately […]
Satsuma launches Phase 3 trial for acute migraine combination product
Satsuma Pharmaceuticals (NSDQ:STSA) has announced that it has enrolled the first patient in its SUMMIT Phase 3 efficacy trial of STS101, a drug-device product that is a potential acute treatment of migraine. STS101 is a nasal powder containing dihydroergotamine (DHE), an analgesic already available to treat migraines and cluster headaches. In fact, migraine patients have […]
